Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1147
Shown on this page
12
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within NYU Langone Health, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 901–912 of 1,147 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting Phase 3 Interventional

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

NCT02468024
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Lung Surgery, Radiation therapy
Procedure · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
40
States / cities
La Jolla, California • Aurora, Colorado • Colorado Springs, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting No phase listed Observational

Pompe Pregnancy Sub-Registry

NCT00567073
Status at this site: Recruiting
View directory record Official record
Conditions
Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2034
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting Not applicable Interventional

Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)

NCT07171684
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Diabetes in Pregnancy, Gestational Diabetes
Interventions
Insulin glargine alone, Insulin glargine + insulin lispro
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Fountain Valley, California • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting Phase 4 Interventional

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

NCT06598397
Status at this site: Recruiting
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Smoking Cessation
Interventions
Motivational Interviewing (MI) Counseling, Peer Mentoring, Skills-based Text Messaging, Combination NRT
Behavioral · Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Active, not recruiting Phase 4 Interventional

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

NCT05983068
Site status not listed — check the official record
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 14 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting Phase 2 Interventional

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

NCT06655454
Status at this site: Recruiting
View directory record Official record
Conditions
Pain Assessment, Quality of Life (QOL), Analgesic Use
Interventions
Supplemental Postoperative Bupivacaine, Placebo Injection
Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Active, not recruiting Phase 4 Interventional

Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder

NCT05391971
Site status not listed — check the official record
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Bupivacaine, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Active, not recruiting Phase 2 Interventional

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265
Drug
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Not yet recruiting Not applicable Interventional

Prospective Multi-center Study Comparing Pulsed Tm:YAG Laser to Pulse Modulated Holmium Laser in the Treatment of Nephrolithiasis With FANS Access Sheaths

NCT07516106
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Stone
Interventions
Moses Holmium:YAG laser, Thulium:YAG laser
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 5, 2026, 10:10 AM EST
Recruiting Phase 1 Interventional

Post-CA Neuroprotection With Magnesium

NCT06455514
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiac Arrest, Return of Spontaneous Circulation
Interventions
Magnesium Sulfate, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 5, 2026, 10:10 AM EST

About this NYU Langone Health institution page

What this page lists
ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.